The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Excellent
I thought, would have at the vaccines we have pitched against in the other trials in the ASCO article find below
1.Evaxion Biotech 26th of April -4.1800
+0.0600 (+1.46%)
Day's Range 4.0500 - 4.2500
52 Week Range 2.8240 - 18.5000
https://www.evaxion-biotech.com
2. BioNtech https://www.biontech.com/int/en/home.html
Prev. Close 86.71
52 Wk. Low 85.21
52 Wk. High 125.83
3. Moderna https://www.modernatx.com/en-GB
Prev. Close 106.18
52 Wk. Low 62.55
52 Wk. High 142.79
4. Scancell https://www.scancell.co.uk
Prev. Close 9.60p
52 Wk. Low 7.59
52 Wk. High 18.29
5.IQ Biotech, Inc
https://iobiotech.com
Prev. Close 1.4500
52 Wk. Low 0.8160
52 Wk. High 2.6400
ASCO PUBLICATIONS
26th of April
“Curing Stage IV Melanoma: Where Have We Been and Where Are We?”
https://ascopubs.org/doi/10.1200/EDBK_438654
scroll down to Cancer Vaccines :
BioNTech (BNT221),57 while Moderna is focusing on the adjuvant melanoma space in collaboration with Merck.58 BioNTech is also the manufacturer of BNT111, a cancer vaccine encoding for a fixed set of four cancer-specific antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE),59 now being evaluated combined with cemiplimab in a randomized prospective trial that has recently completed recruitment (ClinicalTrials.gov identifier: NCT04526899).
Other innovative vaccine approaches in testing include Scancell's DNA plasmid vaccine, SCIB1, which incorporates specific epitopes from proteins gp100 and TRP-2, identified from the cloning of T cells from patients who spontaneously recovered from melanoma. Both proteins play key roles in the production of melanin. Evaluation of the first 12 patients recruited to a phase II trial combining SCIB1 with ipinivo reported a response rate of 83% (ClinicalTrials.gov identifier: NCT04079166). IO102-IO103, manufactured by IO Biotech, targets immunosuppressive proteins such as IDO and PD-L1. The phase I/II trial (KEYNOTE-D18) combined with pembrolizumab and demonstrated an overall response rate of 73% and a CR rate of 47%. These results led to the FDA granting breakthrough designation of the combination, and a confirmatory randomized phase II trial is underway (ClinicalTrials.gov identifier: NCT05280314).
Thanks for clearing that up Bermuda
Good find WTP
the 26 th of April The good law project are questioning Sunak relationship with his fund Thelme and Moderna. A £400,000 Bespoke vaccine per patient ( as the times are now calling it ) a 10 year contract / tie in with the NHS is questionable ? belt and braces measure, after surgery . So how much is the total cost ? tIt’s a very interesting debate. Please read this link.
https://goodlawproject.org/government-ordered-to-disclose-sunaks-hedge-fund-emails/#:~:text=Shortly%20after%20Sunak%20became%20prime,a%20financial%20interest%20in%20Theleme.
Thinking allowed the bespoke vaccine will take longer and be more expensive to produce. So could cause a significant delay
The off the shelf offering from Scancell could reach the required patient numbers quicker
Pros and cons of both vaccines.
Just noticed the headline has changed in The Times from :
Skin cancer jab trial targets high-risk melanomas
New headline
Bespoke cancer vaccine targets tumours in landmark trial
https://www.thetimes.co.uk/article/e23343c5-91c4-49b0-9fa4-c1eec5c2bb2c?shareToken=
As mentioned earlier in the week by Bermuda
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
article
Abstract
Authors
Heather Shaw
Heather Shaw
Mount Vernon Cancer Center
Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Kellati Prasad, Ruth Board, Clare Barlow, James Larkin, Kate Young, Amanda Fitzpatrick, Ioannis Karydis, Maria Marples, Rebecca Lee, Philippa Corrie, Robert Miller, Georgia Goodhew, Fayaz Master, Lindy Durrant
Organizations
Mount Vernon Cancer Center, Nottingham University Hospitals NHS Trust, Churchill Hospital, Velindre Cancer Centre, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust & University of Sheffield, Derriford Hospital, Lancashire University Hospital, Lancashire Teaching Hospitals NHS Trust, Musgrove Park Hospital, Somerset Foundation Trust, The Royal Marsden Hospital NHS Foundation Trust, Royal Marsden Hospital NHS Foundation Trust, Guy’s & St Thomas’ NHS Foundation Trust, University Hospital Southampton NHS Trust, St. James's University Hospital, The Christie NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Scancell Ltd
C11 agree with your point room for more than one type of cancer vaccine Heather Shaw referred to “ these will be game changers in immunology “
See Bermuda post on ASCO earlier in the week . Also heather shaw in on the advisory board for the Scope Trial
Skin cancer jab trial targets high-risk melanomas
https://www.thetimes.co.uk/article/e23343c5-91c4-49b0-9fa4-c1eec5c2bb2c?shareToken=6d03ef8920e19e9d3d4fd5f793fc9d06
Dr Heather Shaw, consultant medical oncologist and the national co-ordinating investigator for the trial, said: “I think there is a real hope that these will be the gamechangers in immunotherapy.”
Each patient has their own personalised jab manufactured within weeks, using mRNA genetic code found in their tumours. When injected, the jab instructs the body to create proteins identical to those found on the surface of tumours, triggering an immune response.
From Bermuda shorts
Really good to see that Heather Shaw, one of the SCIB1 study investigators will be presenting a poster at ASCO in Chicago in June.
SCIB1 & iSCIB1+ - Scancell
The abstract title:-
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
Presenter: Heather May Shaw, MD, FRCP, MRCP | Mount Vernon Cancer Center
Abstract: 9535
| Poster Bd #: 319
ASCO isn't just another scientific conference, it's the largest oncology conference in the world and it would have been disappointing if Scancell were not represented.
wednesday 7 th of august 11:25 am
modi-2, a vaccine targeting ****citrullinated self-epitopes, stimulates potent cd4-mediated anti-tumor responses as a therapy for solid cancers
https://www.immuno-oncologysummit.com/cancer-vaccines?utm_source=linkedin&utm_medium=social&utm_campaign=vjm_final_track_agenda_20240423
abdullah al-omari, phd, scientist, t cell vaccine, scancell ltd.
stresses within the tumor microenvironment mediate post-translational modifications of self-proteins. ****citrullination is the conversion of lysine residues to ****citrulline which can generate neoepitopes and bypass self-tolerance. modi2, a ****citrullinated peptide-snapvax vaccine, stimulates strong th1 responses and anti-tumor immunity in three different murine tumor models. we propose the modi-2 vaccine formulation has potential for translation into clinic in several cancer indications.
Https://synapse.patsnap.com/drug/ceab59ba703544a2a1d8c8da9b59e11a
One live Chanel
22nd of April 24 - ( Linked to relevant content )
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences; director, Cutaneous Oncology Program, GW Cancer Center, discusses the evolving use of PD-1 inhibitors for patients with cutaneous squamous cell carcinoma (CSCC) in the neoadjuvant and adjuvant setting.
https://www.onclive.com/view/dr-patel-on-the-evolving-use-of-neoadjuvant-pd-1-inhibitors-in-cscc
Hopefully all the housekeeping RNS ‘s are out not good for blood pressure at 7 am
And a beefed management team . we should be on track at least AS news arrives on any of the following. With cancer vaccines hitting prime time 🕰️
Good luck to all for tomorrow and The presentation by the CEO
Would appreciate other posters view on the phrase "Clinical Update" don't see how unless the market receives an update via an RNS
would welcome views ?
The current percentages are eye-catching ?
https://www.immuno-oncologyeurope.com/cancer-vaccines
Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination
Lindy Durrant, BSc, PhD, Professor, CEO, Scancell Ltd.
SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial
The break out discussion coming directly after Lindy Durrants talk with be interesting
Cambridge Healthtech Institute's Inaugural
Therapeutic Cancer Vaccines
Immunological Advances for Cancer Treatment
23 - 24 APRIL 2024 ALL TIMES BST
The development of cancer vaccines intended to treat existing forms of cancer have been showing real promise with recent advances in the development of various platforms and progress in clinical development. The goal of these products is to provide a patient’s immune system with the capability to mount a sustained response against a tumor, either to eliminate tumor cells or, at the least, keep those cells under constant surveillance in order to prevent expansion and metastasis. Strategies for both personalized and off-the-shelf products are being developed, typically based on neoantigens, mRNA, or peptides specific to cancer cells. Successful advances will require better understanding of numerous topics, including immunological mechanisms of action, immune monitoring to direct development, dosing and delivery strategies, and how such products can be combined, particularly with checkpoint inhibitors. Emphasis will be placed on programs that have already reached the clinic.
Interactive Breakout Discussions
Interactive Breakout Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing.
TUESDAY, 23 APRIL 2024, 15:15-16:00
Breakout Discussions with Afternoon Refreshments
THERAPEUTIC CANCER VACCINES
TOPIC: The Pros and Cons of Personalized vs Off-the-Shelf Cancer Vaccines
Jonathan Kwok, CEO, Infinitopes
Good luck to one and all , clearly Scancell have something worth listening to ?
Excelling point TF
Why do they think Genmab only paid about 1% of that figure direct to SCLP and the rest milestones as if it was such a dead cert why would SCLP not held out for a much bigger slice of the pie.
It was the first deal . very important because ultimately it was another way of getting one of getting the Glymab platforms into the clinic . no point sitting on it get it into the arena
LD said fine line between what you keep and give away ?
good move I think
Needle in a hay stack
Jeroen Wissink
CEO Uneedle | Intradermic | therapeutic vaccine delivey | cancer immunology
excellent article
We have many millions of mature helper T cells with unique T cell receptors (TCRs) in our body. In case of a serious infection or onset cancer our life depends on just one of them. How the Immune System Actually Works from Philip Dettmer - Kurzgesagd helps us understand.
Unique T cells
This diversity of mature helper T cells is fantastic feature of our immune system, crucial for our body's ability to recognise and respond to diseases and fight the onset of cancer.
We have a cure for any virus, bacteria or mutated cell
So for any virus, bacteria or cancer cell we carry a few matching memory T cells with a corresponding TCR to their antigens. We have the cure in us. Incredible, but true. And this is not new; this part of the immune system has evolved over hundreds of millions of years with us. And not just in humans, it works for most creatures - eaten alive without the immune system - in a similar way.
Dendritic cells to find a single T cell
In case of a serious infection or a cluster of unwanted, mutated cells the dendritic cells - one of the most potent antigen presenting cells - must trigger the helper T cells. Dendritic cells sample unknown or unwanted cells and break them apart to present fragments as antigens on their surface via so called MHC-II molecules.
Target for these antigens presented are the helper T cells, and there are a few helper T cell - somewhere in the body - with the matching receptors (TCR) to the antigen. Dendritic cells must travel to find that specific matching T cell, which is floating somewhere in lymph, in a lymph node. Since there are only a few helper T cells for every unique TCR combination - among many millions of different TCR combinations - it may take a few days before the match is found and before the adaptive immune system kicks in. Relatively slow, but very effective.
A single T cell multiplies
It is considered it a bit of a miracle that the match is always be made. But it is, and this is one of the true beauties of the immune system.
Once found, this unique memory helper T cell is woken up and after some time - remember it has been asleep for years or decades - starts to clone from a single cell to many millions. The counterattack to eliminate the pathogens has begun.
Essentially it is math: the number of specific proteins we - humans and animals, but also the pathogens - can present in the form of an antigen on the surface is limited to a few millions and that seems to be unique enough to uniquely identify viruses, bacteria or cancer antigens as foreign, to be eliminated from the body.
Killer T cells and B cells
At this point the adaptive response becomes more diverse. Some initial helper T cells transform into transform into killer T cells that actually help attack, but most cells transform to do act
Morning
The title of the presentation is intriguing
"Clinical Update on the DC Targeting Melanoma Vaccine, SCIB1 and The Modi-1 Vaccine Targeting Citrullination"
“DC Targeting Melanoma Vaccine”
Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells that regulate adaptive immunity, including against cancer. Therefore, understanding the precise activities of DCs in tumours and patients with cancer is important.
This is an excellent article in nature 24th of Feb
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
https://www.nature.com/articles/s41571-024-00859-1
Key points
* Combining DC-based anticancer treatments with other (immuno)therapies has shown promise in preclinical studies; however, patient selection, treatment sequencing and immunomonitoring require optimization in clinical studies to identify the most synergistic combinations.
* The development of improved DC-based anticancer treatments, including agents targeting DCs in vivo and natural DC-based vaccines produced ex vivo, has the potential to improve patient outcomes and such treatments are generally safe.
This is from Inaco on other board , please cane someone post next link to conference?
From other side
a week away from the next conference
lets hope any update gets an RNS
have we heard about the proposed Doublet in renal ? that was about 10 weeks ago from interims
Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY study pending protocol amendment by the MHRA
Thanks EE. Forgive me
I have had a very busy morning. Only scanned it sorry